person · Reporting owner

KOZIN MARC D

Disclosed activity across 8 companies

Tapewire entity: 19195
SEC CIK: 0001241647

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Decoy Therapeutics Inc.FLKS · Entity 937	Director	July 25, 2018	July 26, 2018
Notable Labs, Ltd.VBLT · Entity 87239	Director	January 01, 2023	January 04, 2023
UFP TECHNOLOGIES INCUFPT · Entity 4409	Director	August 25, 2026	August 27, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Decoy Therapeutics Inc.

Report date July 25, 2018 · Filed July 26, 2018

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.82 · Expires 2028-07-25	Direct	10,000	Reported balance After 2018-07-25 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2018-07-25 · Grant · Acquired 10,000 · Balance 10,000 F1: The stock option will vest in 12 successive equal monthly installments measured from June 6, 2018.

Filing footnotes · ownership attribution and instrument terms

F1: The stock option will vest in 12 successive equal monthly installments measured from June 6, 2018.

Notable Labs, Ltd.

Report date January 01, 2023 · Filed January 04, 2023

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Ordinary SharesSEC Table I · non-derivative	IndirectBy Marc D. Kozin Irrevocable Trust	39,000	Reported balance Holding disclosure · report date 2023-01-01 · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · Balance 39,000 F1: These shares are held by the Marc D. Kozin Irrevocable Trust, of which the Reporting Person's spouse is one of the beneficiaries. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, if any.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.30 · Expires 2036-05-05	Direct	Not disclosed	Reported balance Holding disclosure · report date 2023-01-01 · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · Balance Not disclosed F2: These options were granted on 05/05/16 under the Issuer's Employee Share Ownership and Option Plan (2014) (the "2014 Plan") and are fully vested and exercisable.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.17 · Expires 2040-11-24	Direct	Not disclosed	Reported balance Holding disclosure · report date 2023-01-01 · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · Balance Not disclosed F3: These options were granted on 11/24/20 under the 2014 Plan, with 25% of the shares underlying these options vesting on November 24, 2021 (the one year anniversary of the grant date), and the remainder vesting quarterly thereafter for three years such that they are vested in full on the four-year anniversary of the grant date.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.38 · Expires 2041-07-20	Direct	Not disclosed	Reported balance Holding disclosure · report date 2023-01-01 · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · Balance Not disclosed F4: These options were granted on 07/20/21 under the 2014 Plan, with 25% of the shares underlying these options vesting on July 20, 2022 (the one year anniversary of the grant date), and the remainder vesting quarterly thereafter for three years such that they are vested in full on the four-year anniversary of the grant date.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.31 · Expires 2041-12-07	Direct	Not disclosed	Reported balance Holding disclosure · report date 2023-01-01 · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · Balance Not disclosed F5: These options were granted on 12/07/21 under the 2014 Plan and vest over two years commencing on the grant date such that 50% vest on the first anniversary of the date of grant and the remainder vest quarterly thereafter for one year such that they are vested in full on the two-year anniversary of the grant date.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.12 · Expires 2042-01-02	Direct	Not disclosed	Reported balance Holding disclosure · report date 2023-01-01 · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · Balance Not disclosed F6: These options were granted on 01/02/22 under the 2014 Plan and vest over two years commencing on the grant date such that 50% vest on the first anniversary of the date of grant and the remainder vest quarterly thereafter for one year such that they are vested in full on the two-year anniversary of the grant date.

Filing footnotes · ownership attribution and instrument terms

F1: These shares are held by the Marc D. Kozin Irrevocable Trust, of which the Reporting Person's spouse is one of the beneficiaries. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, if any.

F2: These options were granted on 05/05/16 under the Issuer's Employee Share Ownership and Option Plan (2014) (the "2014 Plan") and are fully vested and exercisable.

F3: These options were granted on 11/24/20 under the 2014 Plan, with 25% of the shares underlying these options vesting on November 24, 2021 (the one year anniversary of the grant date), and the remainder vesting quarterly thereafter for three years such that they are vested in full on the four-year anniversary of the grant date.

F4: These options were granted on 07/20/21 under the 2014 Plan, with 25% of the shares underlying these options vesting on July 20, 2022 (the one year anniversary of the grant date), and the remainder vesting quarterly thereafter for three years such that they are vested in full on the four-year anniversary of the grant date.

F5: These options were granted on 12/07/21 under the 2014 Plan and vest over two years commencing on the grant date such that 50% vest on the first anniversary of the date of grant and the remainder vest quarterly thereafter for one year such that they are vested in full on the two-year anniversary of the grant date.

F6: These options were granted on 01/02/22 under the 2014 Plan and vest over two years commencing on the grant date such that 50% vest on the first anniversary of the date of grant and the remainder vest quarterly thereafter for one year such that they are vested in full on the two-year anniversary of the grant date.

UFP TECHNOLOGIES INC

Report date August 25, 2026 · Filed August 27, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common Stock, $.01 Par ValueSEC Table I · non-derivative	Direct	21,112	Ending reported balance After 2026-08-25 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2026-08-25 · Sale · Disposed 3,650 · Balance 24,462 F1: The Price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $303.58 to $304.49, inclusive. The reporting person undertakes to provide UFP Technologies, Inc., any security holder of UFP Technologies, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Row 2 · 2026-08-25 · Sale · Disposed 3,350 · Balance 21,112 F2: The Price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $304.64 to $305.41, inclusive. The reporting person undertakes to provide UFP Technologies, Inc., any security holder of UFP Technologies, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.

Filing footnotes · ownership attribution and instrument terms

F1: The Price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $303.58 to $304.49, inclusive. The reporting person undertakes to provide UFP Technologies, Inc., any security holder of UFP Technologies, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.

F2: The Price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $304.64 to $305.41, inclusive. The reporting person undertakes to provide UFP Technologies, Inc., any security holder of UFP Technologies, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.

Past disclosures · reporting ended (5)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

CHIMERIX INC

Report date April 21, 2025 · Filed April 21, 2025

Section 16 reporting ended · disclosed 2025-04-21. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.99 · Expires 2034-03-19	Direct	0	Reported balance After 2025-04-21 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2025-04-21 · Disposition to issuer · Disposed 100,000 · Balance 0 F3: Pursuant to the Merger Agreement, each option to purchase Shares (each, an "Option") that was outstanding and unexercised as of immediately prior to the Effective Time, which has a per share exercise price that is less than the Offer Price (an "In the Money Option"), to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and converted into the right to receive a cash payment equal to (i) the excess of (A) the Offer Price over (B) the exercise price payable per Share of such In the Money Option, multiplied by (ii) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time (without regard to vesting). F1: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 4, 2025, by and among Chimerix, Inc. ("Chimerix"), Jazz Pharmaceuticals Public Limited Company ("Parent") and Pinetree Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"). Pursuant to the Merger Agreement, Parent and Purchaser launched a tender offer (the "Offer") for all outstanding shares of common stock of Chimerix (each, a "Share") for an offer price of $8.55 per Share in cash (the "Offer Price"), without interest and subject to reduction for any applicable withholding taxes. The Offer expired at the end of the day, one minute after 11:59 p.m. Eastern Time on April 17, 2025. [continues to Footnote 2] F2: [continues from Footnote 1] On April 21, 2025, following the filing of the certificate of merger with the Secretary of State of the State of Delaware (the "Effective Time"), Purchaser merged with and into Chimerix, with Chimerix continuing as a surviving corporation and an indirect wholly owned subsidiary of Parent (the "Merger"). At the Effective Time, each issued and outstanding Share (other than any Excluded Shares (as such term is defined in the Merger Agreement)) was cancelled in exchange for the right to receive the Offer Price, without any interest and subject to any withholding of applicable taxes.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.89 · Expires 2034-06-19	Direct	0	Reported balance After 2025-04-21 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2025-04-21 · Disposition to issuer · Disposed 60,000 · Balance 0 F3: Pursuant to the Merger Agreement, each option to purchase Shares (each, an "Option") that was outstanding and unexercised as of immediately prior to the Effective Time, which has a per share exercise price that is less than the Offer Price (an "In the Money Option"), to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and converted into the right to receive a cash payment equal to (i) the excess of (A) the Offer Price over (B) the exercise price payable per Share of such In the Money Option, multiplied by (ii) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time (without regard to vesting). F1: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 4, 2025, by and among Chimerix, Inc. ("Chimerix"), Jazz Pharmaceuticals Public Limited Company ("Parent") and Pinetree Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"). Pursuant to the Merger Agreement, Parent and Purchaser launched a tender offer (the "Offer") for all outstanding shares of common stock of Chimerix (each, a "Share") for an offer price of $8.55 per Share in cash (the "Offer Price"), without interest and subject to reduction for any applicable withholding taxes. The Offer expired at the end of the day, one minute after 11:59 p.m. Eastern Time on April 17, 2025. [continues to Footnote 2] F2: [continues from Footnote 1] On April 21, 2025, following the filing of the certificate of merger with the Secretary of State of the State of Delaware (the "Effective Time"), Purchaser merged with and into Chimerix, with Chimerix continuing as a surviving corporation and an indirect wholly owned subsidiary of Parent (the "Merger"). At the Effective Time, each issued and outstanding Share (other than any Excluded Shares (as such term is defined in the Merger Agreement)) was cancelled in exchange for the right to receive the Offer Price, without any interest and subject to any withholding of applicable taxes.

Filing footnotes · ownership attribution and instrument terms

F1: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 4, 2025, by and among Chimerix, Inc. ("Chimerix"), Jazz Pharmaceuticals Public Limited Company ("Parent") and Pinetree Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"). Pursuant to the Merger Agreement, Parent and Purchaser launched a tender offer (the "Offer") for all outstanding shares of common stock of Chimerix (each, a "Share") for an offer price of $8.55 per Share in cash (the "Offer Price"), without interest and subject to reduction for any applicable withholding taxes. The Offer expired at the end of the day, one minute after 11:59 p.m. Eastern Time on April 17, 2025. [continues to Footnote 2]

F2: [continues from Footnote 1] On April 21, 2025, following the filing of the certificate of merger with the Secretary of State of the State of Delaware (the "Effective Time"), Purchaser merged with and into Chimerix, with Chimerix continuing as a surviving corporation and an indirect wholly owned subsidiary of Parent (the "Merger"). At the Effective Time, each issued and outstanding Share (other than any Excluded Shares (as such term is defined in the Merger Agreement)) was cancelled in exchange for the right to receive the Offer Price, without any interest and subject to any withholding of applicable taxes.

F3: Pursuant to the Merger Agreement, each option to purchase Shares (each, an "Option") that was outstanding and unexercised as of immediately prior to the Effective Time, which has a per share exercise price that is less than the Offer Price (an "In the Money Option"), to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and converted into the right to receive a cash payment equal to (i) the excess of (A) the Offer Price over (B) the exercise price payable per Share of such In the Money Option, multiplied by (ii) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time (without regard to vesting).

Dicerna Pharmaceuticals Inc

Report date December 28, 2021 · Filed December 29, 2021

Section 16 reporting ended · disclosed 2021-12-29. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2021-12-28 transaction · row 1 1 source row Row 1 · 2021-12-28 · Disposition to issuer · Disposed 6,333 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 17, 2021, by and among the Issuer, Novo Nordisk A/S, a Danish aktieselskab ("Novo"), and NNUS New Research, Inc., a Delaware corporation and a wholly owned indirect subsidiary of Novo ("Purchaser"), to which Purchaser completed a tender offer for shares of common stock of Issuer, $0.0001 par value per share (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of December 28, 2021 (the "Effective Time"). At the Effective Time, each issued and outstanding Share, including the Reporting Person's Shares, was converted into the right to receive $38.25 per Share, in cash, without interest (the "Offer Price") and subject to any withholding of taxes, upon the terms and conditions of the Merger Agreement. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled.
Common StockSEC Table I · non-derivative	IndirectBy Marc D. Kozin Revocable Trust	Reported balance After 2021-12-28 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2021-12-28 · Disposition to issuer · Disposed 5,000 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 17, 2021, by and among the Issuer, Novo Nordisk A/S, a Danish aktieselskab ("Novo"), and NNUS New Research, Inc., a Delaware corporation and a wholly owned indirect subsidiary of Novo ("Purchaser"), to which Purchaser completed a tender offer for shares of common stock of Issuer, $0.0001 par value per share (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of December 28, 2021 (the "Effective Time"). At the Effective Time, each issued and outstanding Share, including the Reporting Person's Shares, was converted into the right to receive $38.25 per Share, in cash, without interest (the "Offer Price") and subject to any withholding of taxes, upon the terms and conditions of the Merger Agreement. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2021-12-28 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2021-12-28 · Disposition to issuer · Disposed 3,333 · Balance 0 F2: Each restricted stock unit ("RSU") represents the contingent right to receive one Share. F3: At the Effective Time, each Issuer RSU that was then outstanding was cancelled and converted into the right to receive a cash payment equal to (A) the Offer Price multiplied by (B) the total number of Shares subject to such Issuer RSU immediately prior to the Effective Time (without regard to vesting).
Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.31	Direct	Reported balance After 2021-12-28 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2021-12-28 · Disposition to issuer · Disposed 25,000 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to (A) the excess, if any, of (x) the Offer Price over (y) the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time (without regard to vesting).
Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.44	Direct	Reported balance After 2021-12-28 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2021-12-28 · Disposition to issuer · Disposed 25,000 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to (A) the excess, if any, of (x) the Offer Price over (y) the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time (without regard to vesting).
Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.61	Direct	Reported balance After 2021-12-28 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2021-12-28 · Disposition to issuer · Disposed 15,000 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to (A) the excess, if any, of (x) the Offer Price over (y) the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time (without regard to vesting).
Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $30.47	Direct	Reported balance After 2021-12-28 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2021-12-28 · Disposition to issuer · Disposed 15,000 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to (A) the excess, if any, of (x) the Offer Price over (y) the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time (without regard to vesting).

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 17, 2021, by and among the Issuer, Novo Nordisk A/S, a Danish aktieselskab ("Novo"), and NNUS New Research, Inc., a Delaware corporation and a wholly owned indirect subsidiary of Novo ("Purchaser"), to which Purchaser completed a tender offer for shares of common stock of Issuer, $0.0001 par value per share (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of December 28, 2021 (the "Effective Time"). At the Effective Time, each issued and outstanding Share, including the Reporting Person's Shares, was converted into the right to receive $38.25 per Share, in cash, without interest (the "Offer Price") and subject to any withholding of taxes, upon the terms and conditions of the Merger Agreement. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled.

F2: Each restricted stock unit ("RSU") represents the contingent right to receive one Share.

F3: At the Effective Time, each Issuer RSU that was then outstanding was cancelled and converted into the right to receive a cash payment equal to (A) the Offer Price multiplied by (B) the total number of Shares subject to such Issuer RSU immediately prior to the Effective Time (without regard to vesting).

F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to (A) the excess, if any, of (x) the Offer Price over (y) the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time (without regard to vesting).

ENDOCYTE INC

Report date December 21, 2018 · Filed December 21, 2018

Section 16 reporting ended · disclosed 2018-12-21. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2018-12-21 transaction · row 1 Sequence does not reconcile; account continuity is unresolved. 1 source row Row 1 · 2018-12-21 · Disposition to issuer · Disposed 7,800 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of October 17, 2018 (the "Merger Agreement"), by and among Endocyte, Inc. (the "Company"), Novartis AG ("Novartis") and Edinburgh Merger Corporation, a wholly owned subsidiary of Novartis ("Merger Sub"), at the effective time (the "Effective Time") of the merger of Merger Sub with and into the Company, which Effective Time occurred on December 21, 2018, each share of Company common stock was converted into the right to receive an amount in cash equal to $24.00, without interest and less any applicable withholding taxes.
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2018-12-21 transaction · row 2 Sequence does not reconcile; account continuity is unresolved. 1 source row Row 2 · 2018-12-21 · Disposition to issuer · Disposed 3,300 · Balance 0 F2: This restricted stock unit ("RSU") award provided for vesting and settlement 100% on the business day prior to the Company's annual stockholder meeting following May 3, 2018 in the form of one share of Company common stock for each RSU. Pursuant to the Merger Agreement, at the Effective Time, each RSU outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to $24.00, multiplied by the number of shares of Company common stock subject to such RSU, less any applicable withholding taxes.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.71 · Expires 2022-07-25	Direct	Reported balance After 2018-12-21 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2018-12-21 · Disposition to issuer · Disposed 20,000 · Balance 0 F3: This Company stock option was fully vested immediately prior to the Effective Time. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.94 · Expires 2023-06-19	Direct	Reported balance After 2018-12-21 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2018-12-21 · Disposition to issuer · Disposed 14,000 · Balance 0 F3: This Company stock option was fully vested immediately prior to the Effective Time. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.69 · Expires 2024-05-15	Direct	Reported balance After 2018-12-21 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2018-12-21 · Disposition to issuer · Disposed 14,000 · Balance 0 F3: This Company stock option was fully vested immediately prior to the Effective Time. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.02 · Expires 2025-05-14	Direct	Reported balance After 2018-12-21 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2018-12-21 · Disposition to issuer · Disposed 13,500 · Balance 0 F3: This Company stock option was fully vested immediately prior to the Effective Time. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.35 · Expires 2026-05-05	Direct	Reported balance After 2018-12-21 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2018-12-21 · Disposition to issuer · Disposed 13,500 · Balance 0 F3: This Company stock option was fully vested immediately prior to the Effective Time. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.27 · Expires 2027-05-04	Direct	Reported balance After 2018-12-21 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2018-12-21 · Disposition to issuer · Disposed 19,500 · Balance 0 F3: This Company stock option was fully vested immediately prior to the Effective Time. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.81 · Expires 2028-05-03	Direct	Reported balance After 2018-12-21 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2018-12-21 · Disposition to issuer · Disposed 19,500 · Balance 0 F4: This Company stock option was scheduled to vest 100% on the business day prior to the Company's annual stockholder meeting following May 3, 2018. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Agreement and Plan of Merger, dated as of October 17, 2018 (the "Merger Agreement"), by and among Endocyte, Inc. (the "Company"), Novartis AG ("Novartis") and Edinburgh Merger Corporation, a wholly owned subsidiary of Novartis ("Merger Sub"), at the effective time (the "Effective Time") of the merger of Merger Sub with and into the Company, which Effective Time occurred on December 21, 2018, each share of Company common stock was converted into the right to receive an amount in cash equal to $24.00, without interest and less any applicable withholding taxes.

F2: This restricted stock unit ("RSU") award provided for vesting and settlement 100% on the business day prior to the Company's annual stockholder meeting following May 3, 2018 in the form of one share of Company common stock for each RSU. Pursuant to the Merger Agreement, at the Effective Time, each RSU outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to $24.00, multiplied by the number of shares of Company common stock subject to such RSU, less any applicable withholding taxes.

F3: This Company stock option was fully vested immediately prior to the Effective Time. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes.

F4: This Company stock option was scheduled to vest 100% on the business day prior to the Company's annual stockholder meeting following May 3, 2018. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes.

Isleworth Healthcare Acquisition Corp.

Report date September 08, 2021 · Filed September 10, 2021

Section 16 reporting ended · disclosed 2021-09-10. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Reported balance After 2021-09-08 transaction · row 1 1 source row Row 1 · 2021-09-08 · Other · Disposed 36,000 · Balance 0 F1: In connection with the resignation of the reporting person from the Issuer's board of directors, the reporting person transferred for no consideration 36,000 shares of Issuer common stock to the new director of the Issuer filling the vacancy left by the reporting person's resignation.

Filing footnotes · ownership attribution and instrument terms

F1: In connection with the resignation of the reporting person from the Issuer's board of directors, the reporting person transferred for no consideration 36,000 shares of Issuer common stock to the new director of the Issuer filling the vacancy left by the reporting person's resignation.

Tempest Therapeutics, Inc.

Report date December 07, 2018 · Filed December 12, 2018

Section 16 reporting ended · disclosed 2018-12-12. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	7,740	Reported balance After 2018-12-07 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2018-12-07 · Grant · Acquired 831 · Balance 7,740 F1: The shares reported on this Form 4 were issued to the Reporting Person, who elected to take shares in lieu of $5,000 of cash compensation for services as a director and committee member, pursuant to the Issuer's non-employee director compensation plan. F2: Reflects the reverse stock split of Millendo common stock, effective as of December 7, 2018.

Filing footnotes · ownership attribution and instrument terms

F1: The shares reported on this Form 4 were issued to the Reporting Person, who elected to take shares in lieu of $5,000 of cash compensation for services as a director and committee member, pursuant to the Issuer's non-employee director compensation plan.

F2: Reflects the reverse stock split of Millendo common stock, effective as of December 7, 2018.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
August 25, 2026 Filed Aug 27, 2026 22:37 UTC	UFP TECHNOLOGIES INC UFPT · Entity 4409	SaleCommon Stock, $.01 Par Value	3,350	$305.07	$1,021,984.50	Disclosure SEC source: 0002084956-26-000064 · form4.xml · nonDerivative · entry 2 KOZIN MARC D · CIK 0001241647 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,112 F2 · price: The Price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $304.64 to $305.41, inclusive. The reporting person undertakes to provide UFP Technologies, Inc., any security holder of UFP Technologies, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document
August 25, 2026 Filed Aug 27, 2026 22:37 UTC	UFP TECHNOLOGIES INC UFPT · Entity 4409	SaleCommon Stock, $.01 Par Value	3,650	$303.97	$1,109,490.50	Disclosure SEC source: 0002084956-26-000064 · form4.xml · nonDerivative · entry 1 KOZIN MARC D · CIK 0001241647 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,462 F1 · price: The Price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $303.58 to $304.49, inclusive. The reporting person undertakes to provide UFP Technologies, Inc., any security holder of UFP Technologies, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document
June 04, 2026 Filed Jun 8, 2026 16:33 UTC	UFP TECHNOLOGIES INC UFPT · Entity 4409	GrantCommon Stock, $.01 Par Value	802	$0.00	$0.00	Disclosure SEC source: 0002084956-26-000035 · form4.xml · nonDerivative · entry 1 KOZIN MARC D · CIK 0001241647 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,112 F1 · shares: Represents restricted stock units issued under the issuer's 2009 Non-Employee Director Stock Incentive Plan that are to be settled solely in shares of Common Stock. The units vest with respect to 100% of the shares on May 31, 2027, so long as the recipient continues as a director of the Issuer through the vesting date. Read SEC document
June 04, 2025 Filed Jun 6, 2025 18:47 UTC	UFP TECHNOLOGIES INC UFPT · Entity 4409	GrantCommon Stock, $.01 Par Value	625	$0.00	$0.00	Disclosure SEC source: 0001062993-25-011131 · form4.xml · nonDerivative · entry 1 KOZIN MARC D · CIK 0001241647 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,310 F1 · shares: Represents restricted stock units issued under the issuer's 2009 Non-Employee Director Stock Incentive Plan that are to be settled solely in shares of Common Stock. The units vest with respect to 100% of the shares on May 31, 2026, so long as the recipient continues as a director of the Issuer through the vesting date. Read SEC document
April 21, 2025 Filed Apr 21, 2025 16:11 UTC	CHIMERIX INC CMRX · Entity 80651	Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative	60,000	Not disclosed Strike: $0.89	Not disclosed	Disclosure SEC source: 0001415889-25-011071 · form4-04212025_080404.xml · derivative · entry 2 KOZIN MARC D · CIK 0001241647 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 60,000 shares Expires 2034-06-19 F3 · price: Pursuant to the Merger Agreement, each option to purchase Shares (each, an "Option") that was outstanding and unexercised as of immediately prior to the Effective Time, which has a per share exercise price that is less than the Offer Price (an "In the Money Option"), to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and converted into the right to receive a cash payment equal to (i) the excess of (A) the Offer Price over (B) the exercise price payable per Share of such In the Money Option, multiplied by (ii) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time (without regard to vesting). F1 · derivative.exercise_date: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 4, 2025, by and among Chimerix, Inc. ("Chimerix"), Jazz Pharmaceuticals Public Limited Company ("Parent") and Pinetree Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"). Pursuant to the Merger Agreement, Parent and Purchaser launched a tender offer (the "Offer") for all outstanding shares of common stock of Chimerix (each, a "Share") for an offer price of $8.55 per Share in cash (the "Offer Price"), without interest and subject to reduction for any applicable withholding taxes. The Offer expired at the end of the day, one minute after 11:59 p.m. Eastern Time on April 17, 2025. [continues to Footnote 2] F2 · derivative.exercise_date: [continues from Footnote 1] On April 21, 2025, following the filing of the certificate of merger with the Secretary of State of the State of Delaware (the "Effective Time"), Purchaser merged with and into Chimerix, with Chimerix continuing as a surviving corporation and an indirect wholly owned subsidiary of Parent (the "Merger"). At the Effective Time, each issued and outstanding Share (other than any Excluded Shares (as such term is defined in the Merger Agreement)) was cancelled in exchange for the right to receive the Offer Price, without any interest and subject to any withholding of applicable taxes. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, each option to purchase Shares (each, an "Option") that was outstanding and unexercised as of immediately prior to the Effective Time, which has a per share exercise price that is less than the Offer Price (an "In the Money Option"), to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and converted into the right to receive a cash payment equal to (i) the excess of (A) the Offer Price over (B) the exercise price payable per Share of such In the Money Option, multiplied by (ii) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time (without regard to vesting). Read SEC document
April 21, 2025 Filed Apr 21, 2025 16:11 UTC	CHIMERIX INC CMRX · Entity 80651	Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative	100,000	Not disclosed Strike: $0.99	Not disclosed	Disclosure SEC source: 0001415889-25-011071 · form4-04212025_080404.xml · derivative · entry 1 KOZIN MARC D · CIK 0001241647 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 100,000 shares Expires 2034-03-19 F3 · price: Pursuant to the Merger Agreement, each option to purchase Shares (each, an "Option") that was outstanding and unexercised as of immediately prior to the Effective Time, which has a per share exercise price that is less than the Offer Price (an "In the Money Option"), to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and converted into the right to receive a cash payment equal to (i) the excess of (A) the Offer Price over (B) the exercise price payable per Share of such In the Money Option, multiplied by (ii) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time (without regard to vesting). F1 · derivative.exercise_date: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 4, 2025, by and among Chimerix, Inc. ("Chimerix"), Jazz Pharmaceuticals Public Limited Company ("Parent") and Pinetree Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"). Pursuant to the Merger Agreement, Parent and Purchaser launched a tender offer (the "Offer") for all outstanding shares of common stock of Chimerix (each, a "Share") for an offer price of $8.55 per Share in cash (the "Offer Price"), without interest and subject to reduction for any applicable withholding taxes. The Offer expired at the end of the day, one minute after 11:59 p.m. Eastern Time on April 17, 2025. [continues to Footnote 2] F2 · derivative.exercise_date: [continues from Footnote 1] On April 21, 2025, following the filing of the certificate of merger with the Secretary of State of the State of Delaware (the "Effective Time"), Purchaser merged with and into Chimerix, with Chimerix continuing as a surviving corporation and an indirect wholly owned subsidiary of Parent (the "Merger"). At the Effective Time, each issued and outstanding Share (other than any Excluded Shares (as such term is defined in the Merger Agreement)) was cancelled in exchange for the right to receive the Offer Price, without any interest and subject to any withholding of applicable taxes. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, each option to purchase Shares (each, an "Option") that was outstanding and unexercised as of immediately prior to the Effective Time, which has a per share exercise price that is less than the Offer Price (an "In the Money Option"), to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and converted into the right to receive a cash payment equal to (i) the excess of (A) the Offer Price over (B) the exercise price payable per Share of such In the Money Option, multiplied by (ii) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time (without regard to vesting). Read SEC document
September 06, 2024 Filed Oct 3, 2024 19:42 UTC	UFP TECHNOLOGIES INC UFPT · Entity 4409	GiftCommon Stock, $.01 Par Value	1,500	$0.00	$0.00	Disclosure SEC source: 0001062993-24-017375 · form4.xml · nonDerivative · entry 1 KOZIN MARC D · CIK 0001241647 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,685 Read SEC document
June 20, 2024 Filed Jun 21, 2024 11:11 UTC	CHIMERIX INC CMRX · Entity 80651	GrantStock Option (Right to Buy) · Derivative	60,000	$0.00 Strike: $0.89	$0.00	Disclosure SEC source: 0001415889-24-017770 · form4-06212024_030618.xml · derivative · entry 1 KOZIN MARC D · CIK 0001241647 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2034-06-19 F1 · derivative.exercise_date: The shares subject to the option vest in a series of 12 equal monthly installments from the date of grant; provided, however, that the option shall become fully vested on the date that is the earlier of (i) the one-year anniversary of the date of grant and (ii) the date of the Company's 2024 annual stockholder meeting. Read SEC document
June 05, 2024 Filed Jun 7, 2024 22:07 UTC	UFP TECHNOLOGIES INC UFPT · Entity 4409	GrantStock Option (Right to Buy) · Derivative	493	$0.00 Strike: $260.92	$0.00	Disclosure SEC source: 0001062993-24-012212 · form4.xml · derivative · entry 2 KOZIN MARC D · CIK 0001241647 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 493 Underlying: Common Stock, $.01 Par Value · 493 shares Expires 2034-06-05 Read SEC document
June 05, 2024 Filed Jun 7, 2024 22:07 UTC	UFP TECHNOLOGIES INC UFPT · Entity 4409	GrantCommon Stock, $.01 Par Value	230	$0.00	$0.00	Disclosure SEC source: 0001062993-24-012212 · form4.xml · nonDerivative · entry 1 KOZIN MARC D · CIK 0001241647 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,185 F1 · shares: Represents restricted stock units issued under the issuer's 2009 Non-Employee Director Stock Incentive Plan that are to be settled solely in shares of Common Stock. The units vest with respect to 100% of the shares on May 31, 2025, so long as the recipient continues as a director of the Issuer through the vesting date. Read SEC document
March 20, 2024 Filed Mar 21, 2024 16:10 UTC	CHIMERIX INC CMRX · Entity 80651	GrantStock Option (Right to Buy) · Derivative	100,000	$0.00 Strike: $0.99	$0.00	Disclosure SEC source: 0001415889-24-008833 · form4-03212024_080334.xml · derivative · entry 1 KOZIN MARC D · CIK 0001241647 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2034-03-19 F1 · derivative.exercise_date: One-third of the shares subject to the stock option will vest and become exercisable on March 20, 2025 and the balance of the shares will vest in a series of 24 equal monthly installments thereafter, such that the option will be fully vested on March 20, 2027, subject to Reporting Person's Continuous Service (as defined in the Plan) through each such vesting date and will vest in full upon a Change in Control (as defined in the Plan). Read SEC document
June 07, 2023 Filed Jun 8, 2023 23:27 UTC	UFP TECHNOLOGIES INC UFPT · Entity 4409	GrantStock Option (Right to Buy) · Derivative	703	$0.00 Strike: $167.98	$0.00	Disclosure SEC source: 0001062993-23-013202 · form4.xml · derivative · entry 2 KOZIN MARC D · CIK 0001241647 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 703 Underlying: Common Stock, $.01 Par Value · 703 shares Expires 2033-06-07 Read SEC document
June 07, 2023 Filed Jun 8, 2023 23:27 UTC	UFP TECHNOLOGIES INC UFPT · Entity 4409	GrantCommon Stock, $.01 Par Value	298	$0.00	$0.00	Disclosure SEC source: 0001062993-23-013202 · form4.xml · nonDerivative · entry 1 KOZIN MARC D · CIK 0001241647 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,955 F1 · shares: Represents restricted stock units issued under the issuer's 2009 Non-Employee Director Stock Incentive Plan that are to be settled solely in shares of Common Stock. The units vest with respect to 100% of the shares on May 31, 2024, so long as the recipient continues as a director of the Issuer through the vesting date. Read SEC document
March 10, 2023 Filed Mar 10, 2023 20:10 UTC	UFP TECHNOLOGIES INC UFPT · Entity 4409	GiftCommon Stock, $.01 Par Value	1,000	$0.00	$0.00	Disclosure SEC source: 0001062993-23-006525 · form4.xml · nonDerivative · entry 1 KOZIN MARC D · CIK 0001241647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,657 Read SEC document
June 08, 2022 Filed Jun 10, 2022 21:18 UTC	UFP TECHNOLOGIES INC UFPT · Entity 4409	GrantStock Option (Right to Buy) · Derivative	1,646	$0.00 Strike: $77.28	$0.00	Disclosure SEC source: 0001240679-22-000039 · edgar.xml · derivative · entry 2 KOZIN MARC D · CIK 0001241647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,646 Underlying: Common Stock, $.01 Par Value · 1,646 shares Expires 2032-06-08 Read SEC document
June 08, 2022 Filed Jun 10, 2022 21:18 UTC	UFP TECHNOLOGIES INC UFPT · Entity 4409	GrantCommon Stock, $.01 Par Value	647	$0.00	$0.00	Disclosure SEC source: 0001240679-22-000039 · edgar.xml · nonDerivative · entry 1 KOZIN MARC D · CIK 0001241647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,657 F1 · shares: Represents restricted stock units issued under the issuer's 2009 Non-Employee Director Stock Incentive Plan that are to be settled solely in shares of Common Stock. The units vest with respect to 100% of the shares on May 31, 2023, so long as the recipient continues as a director of the Issuer through the vesting date. Read SEC document
December 28, 2021 Filed Dec 29, 2021 21:21 UTC	Dicerna Pharmaceuticals Inc DRNA · Entity 131951	Disposition to issuerDirector Stock Option (Right to Buy) · Derivative	15,000	Not disclosed Strike: $30.47	Not disclosed	Disclosure SEC source: 0001399529-21-000202 · wf-form4_164081284688017.xml · derivative · entry 7 KOZIN MARC D · CIK 0001241647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires not disclosed F4 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to (A) the excess, if any, of (x) the Offer Price over (y) the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time (without regard to vesting). F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to (A) the excess, if any, of (x) the Offer Price over (y) the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time (without regard to vesting). F4 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to (A) the excess, if any, of (x) the Offer Price over (y) the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time (without regard to vesting). Read SEC document
December 28, 2021 Filed Dec 29, 2021 21:21 UTC	Dicerna Pharmaceuticals Inc DRNA · Entity 131951	Disposition to issuerDirector Stock Option (Right to Buy) · Derivative	15,000	Not disclosed Strike: $21.61	Not disclosed	Disclosure SEC source: 0001399529-21-000202 · wf-form4_164081284688017.xml · derivative · entry 6 KOZIN MARC D · CIK 0001241647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires not disclosed F4 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to (A) the excess, if any, of (x) the Offer Price over (y) the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time (without regard to vesting). F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to (A) the excess, if any, of (x) the Offer Price over (y) the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time (without regard to vesting). F4 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to (A) the excess, if any, of (x) the Offer Price over (y) the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time (without regard to vesting). Read SEC document
December 28, 2021 Filed Dec 29, 2021 21:21 UTC	Dicerna Pharmaceuticals Inc DRNA · Entity 131951	Disposition to issuerDirector Stock Option (Right to Buy) · Derivative	25,000	Not disclosed Strike: $15.44	Not disclosed	Disclosure SEC source: 0001399529-21-000202 · wf-form4_164081284688017.xml · derivative · entry 5 KOZIN MARC D · CIK 0001241647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires not disclosed F4 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to (A) the excess, if any, of (x) the Offer Price over (y) the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time (without regard to vesting). F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to (A) the excess, if any, of (x) the Offer Price over (y) the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time (without regard to vesting). F4 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to (A) the excess, if any, of (x) the Offer Price over (y) the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time (without regard to vesting). Read SEC document
December 28, 2021 Filed Dec 29, 2021 21:21 UTC	Dicerna Pharmaceuticals Inc DRNA · Entity 131951	Disposition to issuerDirector Stock Option (Right to Buy) · Derivative	25,000	Not disclosed Strike: $10.31	Not disclosed	Disclosure SEC source: 0001399529-21-000202 · wf-form4_164081284688017.xml · derivative · entry 4 KOZIN MARC D · CIK 0001241647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires not disclosed F4 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to (A) the excess, if any, of (x) the Offer Price over (y) the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time (without regard to vesting). F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to (A) the excess, if any, of (x) the Offer Price over (y) the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time (without regard to vesting). F4 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to (A) the excess, if any, of (x) the Offer Price over (y) the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time (without regard to vesting). Read SEC document
December 28, 2021 Filed Dec 29, 2021 21:21 UTC	Dicerna Pharmaceuticals Inc DRNA · Entity 131951	Disposition to issuerRestricted Stock Units · Derivative	3,333	Not disclosed	Not disclosed	Disclosure SEC source: 0001399529-21-000202 · wf-form4_164081284688017.xml · derivative · entry 3 KOZIN MARC D · CIK 0001241647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,333 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the contingent right to receive one Share. F3 · price: At the Effective Time, each Issuer RSU that was then outstanding was cancelled and converted into the right to receive a cash payment equal to (A) the Offer Price multiplied by (B) the total number of Shares subject to such Issuer RSU immediately prior to the Effective Time (without regard to vesting). F3 · derivative.exercise_date: At the Effective Time, each Issuer RSU that was then outstanding was cancelled and converted into the right to receive a cash payment equal to (A) the Offer Price multiplied by (B) the total number of Shares subject to such Issuer RSU immediately prior to the Effective Time (without regard to vesting). F3 · derivative.expiration_date: At the Effective Time, each Issuer RSU that was then outstanding was cancelled and converted into the right to receive a cash payment equal to (A) the Offer Price multiplied by (B) the total number of Shares subject to such Issuer RSU immediately prior to the Effective Time (without regard to vesting). Read SEC document
December 28, 2021 Filed Dec 29, 2021 21:21 UTC	Dicerna Pharmaceuticals Inc DRNA · Entity 131951	Disposition to issuerCommon Stock	5,000	$38.25	$191,250.00	Disclosure SEC source: 0001399529-21-000202 · wf-form4_164081284688017.xml · nonDerivative · entry 2 KOZIN MARC D · CIK 0001241647 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Marc D. Kozin Revocable Trust Disclosed balance after: 0 F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 17, 2021, by and among the Issuer, Novo Nordisk A/S, a Danish aktieselskab ("Novo"), and NNUS New Research, Inc., a Delaware corporation and a wholly owned indirect subsidiary of Novo ("Purchaser"), to which Purchaser completed a tender offer for shares of common stock of Issuer, $0.0001 par value per share (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of December 28, 2021 (the "Effective Time"). At the Effective Time, each issued and outstanding Share, including the Reporting Person's Shares, was converted into the right to receive $38.25 per Share, in cash, without interest (the "Offer Price") and subject to any withholding of taxes, upon the terms and conditions of the Merger Agreement. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled. F1 · shares: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 17, 2021, by and among the Issuer, Novo Nordisk A/S, a Danish aktieselskab ("Novo"), and NNUS New Research, Inc., a Delaware corporation and a wholly owned indirect subsidiary of Novo ("Purchaser"), to which Purchaser completed a tender offer for shares of common stock of Issuer, $0.0001 par value per share (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of December 28, 2021 (the "Effective Time"). At the Effective Time, each issued and outstanding Share, including the Reporting Person's Shares, was converted into the right to receive $38.25 per Share, in cash, without interest (the "Offer Price") and subject to any withholding of taxes, upon the terms and conditions of the Merger Agreement. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled. F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 17, 2021, by and among the Issuer, Novo Nordisk A/S, a Danish aktieselskab ("Novo"), and NNUS New Research, Inc., a Delaware corporation and a wholly owned indirect subsidiary of Novo ("Purchaser"), to which Purchaser completed a tender offer for shares of common stock of Issuer, $0.0001 par value per share (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of December 28, 2021 (the "Effective Time"). At the Effective Time, each issued and outstanding Share, including the Reporting Person's Shares, was converted into the right to receive $38.25 per Share, in cash, without interest (the "Offer Price") and subject to any withholding of taxes, upon the terms and conditions of the Merger Agreement. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled. Read SEC document
December 28, 2021 Filed Dec 29, 2021 21:21 UTC	Dicerna Pharmaceuticals Inc DRNA · Entity 131951	Disposition to issuerCommon Stock	6,333	$38.25	$242,237.25	Disclosure SEC source: 0001399529-21-000202 · wf-form4_164081284688017.xml · nonDerivative · entry 1 KOZIN MARC D · CIK 0001241647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 17, 2021, by and among the Issuer, Novo Nordisk A/S, a Danish aktieselskab ("Novo"), and NNUS New Research, Inc., a Delaware corporation and a wholly owned indirect subsidiary of Novo ("Purchaser"), to which Purchaser completed a tender offer for shares of common stock of Issuer, $0.0001 par value per share (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of December 28, 2021 (the "Effective Time"). At the Effective Time, each issued and outstanding Share, including the Reporting Person's Shares, was converted into the right to receive $38.25 per Share, in cash, without interest (the "Offer Price") and subject to any withholding of taxes, upon the terms and conditions of the Merger Agreement. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled. F1 · shares: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 17, 2021, by and among the Issuer, Novo Nordisk A/S, a Danish aktieselskab ("Novo"), and NNUS New Research, Inc., a Delaware corporation and a wholly owned indirect subsidiary of Novo ("Purchaser"), to which Purchaser completed a tender offer for shares of common stock of Issuer, $0.0001 par value per share (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of December 28, 2021 (the "Effective Time"). At the Effective Time, each issued and outstanding Share, including the Reporting Person's Shares, was converted into the right to receive $38.25 per Share, in cash, without interest (the "Offer Price") and subject to any withholding of taxes, upon the terms and conditions of the Merger Agreement. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled. F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 17, 2021, by and among the Issuer, Novo Nordisk A/S, a Danish aktieselskab ("Novo"), and NNUS New Research, Inc., a Delaware corporation and a wholly owned indirect subsidiary of Novo ("Purchaser"), to which Purchaser completed a tender offer for shares of common stock of Issuer, $0.0001 par value per share (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of December 28, 2021 (the "Effective Time"). At the Effective Time, each issued and outstanding Share, including the Reporting Person's Shares, was converted into the right to receive $38.25 per Share, in cash, without interest (the "Offer Price") and subject to any withholding of taxes, upon the terms and conditions of the Merger Agreement. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled. Read SEC document
September 08, 2021 Filed Sep 10, 2021 21:20 UTC	Isleworth Healthcare Acquisition Corp. ISLE · Entity 135573	OtherCommon Stock	36,000	$0.00	$0.00	Disclosure SEC source: 0000899243-21-035571 · doc4.xml · nonDerivative · entry 1 KOZIN MARC D · CIK 0001241647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: In connection with the resignation of the reporting person from the Issuer's board of directors, the reporting person transferred for no consideration 36,000 shares of Issuer common stock to the new director of the Issuer filling the vacancy left by the reporting person's resignation. F1 · price: In connection with the resignation of the reporting person from the Issuer's board of directors, the reporting person transferred for no consideration 36,000 shares of Issuer common stock to the new director of the Issuer filling the vacancy left by the reporting person's resignation. Read SEC document
August 10, 2021 Filed Aug 10, 2021 22:44 UTC	Dicerna Pharmaceuticals Inc DRNA · Entity 131951	PurchaseCommon Stock	3,000	$23.66	$70,986.00	Disclosure SEC source: 0001399529-21-000144 · wf-form4_162863546792743.xml · nonDerivative · entry 1 KOZIN MARC D · CIK 0001241647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,333 F1 · price: The price reported in Column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $23.455 to $23.840, inclusive. The Reporting Person undertakes to provide to Dicerna Pharmaceuticals, Inc., any security holder of Dicerna Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4. Read SEC document
June 09, 2021 Filed Jun 11, 2021 16:50 UTC	UFP TECHNOLOGIES INC UFPT · Entity 4409	GrantStock Option (Right to Buy) · Derivative	1,786	$0.00 Strike: $57.34	$0.00	Disclosure SEC source: 0001240679-21-000044 · edgar.xml · derivative · entry 2 KOZIN MARC D · CIK 0001241647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,786 Underlying: Common Stock, $.01 Par Value · 1,786 shares Expires 2031-06-09 Read SEC document
June 09, 2021 Filed Jun 11, 2021 16:50 UTC	UFP TECHNOLOGIES INC UFPT · Entity 4409	GrantCommon Stock, $.01 Par Value	610	$0.00	$0.00	Disclosure SEC source: 0001240679-21-000044 · edgar.xml · nonDerivative · entry 1 KOZIN MARC D · CIK 0001241647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,010 F1 · shares: Represents restricted stock units issued under the issuer's 2009 Non-Employee Director Stock Incentive Plan that are to be settled solely in shares of Common Stock. The units vest with respect to 100% of the shares on May 31, 2022, so long as the recipient continues as a director of the Issuer through the vesting date. Read SEC document
June 03, 2021 Filed Jun 8, 2021 01:35 UTC	Dicerna Pharmaceuticals Inc DRNA · Entity 131951	GrantDirector Stock Option (Right to Buy) · Derivative	15,000	$0.00 Strike: $30.47	$0.00	Disclosure SEC source: 0001399529-21-000109 · wf-form4_162311608345843.xml · derivative · entry 5 KOZIN MARC D · CIK 0001241647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2031-06-02 F4 · derivative.exercise_date: This option vests monthly over 12 months from the Grant Date in substantially equal monthly installments, provided that the option will vest in full on the next regularly scheduled annual meeting of the stockholders of the Issuer that occurs following the Grant Date, subject to the Reporting Person's continued service to the Issuer as a director through each such date or, if earlier, such annual meeting. Read SEC document
June 03, 2021 Filed Jun 8, 2021 01:35 UTC	Dicerna Pharmaceuticals Inc DRNA · Entity 131951	GrantRestricted Stock Units · Derivative	3,333	$0.00	$0.00	Disclosure SEC source: 0001399529-21-000109 · wf-form4_162311608345843.xml · derivative · entry 4 KOZIN MARC D · CIK 0001241647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,333 Underlying: Common Stock · 3,333 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the contingent right to receive one share of the Issuer's Common Stock. F3 · derivative.exercise_date: Represents RSUs that shall vest and become nonforfeitable with respect to one-hundred percent (100%) of the total number of RSUs on the earlier of (i) 12 months from June 3, 2021 ("Grant Date") and (ii) the next regularly scheduled annual meeting of stockholders of the Issuer that occurs following the Grant Date, subject to the Reporting Person's continued service to the Issuer as a director through such date or, if earlier, such annual meeting. F3 · derivative.expiration_date: Represents RSUs that shall vest and become nonforfeitable with respect to one-hundred percent (100%) of the total number of RSUs on the earlier of (i) 12 months from June 3, 2021 ("Grant Date") and (ii) the next regularly scheduled annual meeting of stockholders of the Issuer that occurs following the Grant Date, subject to the Reporting Person's continued service to the Issuer as a director through such date or, if earlier, such annual meeting. Read SEC document
June 03, 2021 Filed Jun 8, 2021 01:35 UTC	Dicerna Pharmaceuticals Inc DRNA · Entity 131951	Exercise / conversionRestricted Stock Units · Derivative	3,333	$0.00	$0.00	Disclosure SEC source: 0001399529-21-000109 · wf-form4_162311608345843.xml · derivative · entry 3 KOZIN MARC D · CIK 0001241647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,333 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the contingent right to receive one share of the Issuer's Common Stock. F2 · derivative.exercise_date: Represents RSUs that vested and became nonforfeitable with respect to one-hundred percent (100%) of the total number of RSUs on June 3, 2021. F2 · derivative.expiration_date: Represents RSUs that vested and became nonforfeitable with respect to one-hundred percent (100%) of the total number of RSUs on June 3, 2021. Read SEC document
June 03, 2021 Filed Jun 8, 2021 01:35 UTC	Dicerna Pharmaceuticals Inc DRNA · Entity 131951	Exercise / conversionCommon Stock	3,333	Not disclosed	Not disclosed	Disclosure SEC source: 0001399529-21-000109 · wf-form4_162311608345843.xml · nonDerivative · entry 1 KOZIN MARC D · CIK 0001241647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,333 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents the contingent right to receive one share of the Issuer's Common Stock. Read SEC document
March 08, 2021 Filed Mar 10, 2021 17:29 UTC	UFP TECHNOLOGIES INC UFPT · Entity 4409	GiftCommon Stock, $.01 Par Value	4,000	$0.00	$0.00	Disclosure SEC source: 0001240679-21-000022 · edgar.xml · nonDerivative · entry 6 KOZIN MARC D · CIK 0001241647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,400 Read SEC document
March 08, 2021 Filed Mar 10, 2021 17:29 UTC	UFP TECHNOLOGIES INC UFPT · Entity 4409	SaleCommon Stock, $.01 Par Value	600	$54.97	$32,982.00	Disclosure SEC source: 0001240679-21-000022 · edgar.xml · nonDerivative · entry 5 KOZIN MARC D · CIK 0001241647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,400 F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $54.91 to $55.10, inclusive. The reporting person undertakes to provide to UFP Technologies, Inc., any security holder of UFP Technologies, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document
March 08, 2021 Filed Mar 10, 2021 17:29 UTC	UFP TECHNOLOGIES INC UFPT · Entity 4409	SaleCommon Stock, $.01 Par Value	8,466	$54.35	$460,127.10	Disclosure SEC source: 0001240679-21-000022 · edgar.xml · nonDerivative · entry 4 KOZIN MARC D · CIK 0001241647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,000 F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $53.90 to $54.90, inclusive. The reporting person undertakes to provide to UFP Technologies, Inc., any security holder of UFP Technologies, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document
March 08, 2021 Filed Mar 10, 2021 17:29 UTC	UFP TECHNOLOGIES INC UFPT · Entity 4409	SaleCommon Stock, $.01 Par Value	200	$52.59	$10,518.00	Disclosure SEC source: 0001240679-21-000022 · edgar.xml · nonDerivative · entry 3 KOZIN MARC D · CIK 0001241647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,466 Read SEC document
March 08, 2021 Filed Mar 10, 2021 17:29 UTC	UFP TECHNOLOGIES INC UFPT · Entity 4409	SaleCommon Stock, $.01 Par Value	234	$51.28	$11,999.52	Disclosure SEC source: 0001240679-21-000022 · edgar.xml · nonDerivative · entry 2 KOZIN MARC D · CIK 0001241647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,666 F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $51.28 to $51.32, inclusive. The reporting person undertakes to provide to UFP Technologies, Inc., any security holder of UFP Technologies, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document
March 08, 2021 Filed Mar 10, 2021 17:29 UTC	UFP TECHNOLOGIES INC UFPT · Entity 4409	SaleCommon Stock, $.01 Par Value	500	$50.66	$25,330.00	Disclosure SEC source: 0001240679-21-000022 · edgar.xml · nonDerivative · entry 1 KOZIN MARC D · CIK 0001241647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,900 F1 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $50.19 to $51.01, inclusive. The reporting person undertakes to provide to UFP Technologies, Inc., any security holder of UFP Technologies, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document
June 15, 2020 Filed Jun 17, 2020 00:00 UTC	Dicerna Pharmaceuticals Inc DRNA · Entity 131951	GrantDirector Stock Option (Right to Buy) · Derivative	15,000	$0.00 Strike: $21.61	$0.00	Disclosure SEC source: 0000899243-20-016725 · doc4.xml · derivative · entry 2 KOZIN MARC D · CIK 0001241647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2030-06-14 F2 · derivative.exercise_date: This option vests monthly over 12 months from the Grant Date in substantially equal monthly installments, provided that the option vests in full on the Issuer's next regularly scheduled annual meeting of stockholders that occurs following the Grant Date, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date or, if earlier, such annual meeting. Read SEC document
June 15, 2020 Filed Jun 17, 2020 00:00 UTC	Dicerna Pharmaceuticals Inc DRNA · Entity 131951	GrantRestricted Stock Units · Derivative	3,333	$0.00	$0.00	Disclosure SEC source: 0000899243-20-016725 · doc4.xml · derivative · entry 1 KOZIN MARC D · CIK 0001241647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,333 Underlying: Common Stock · 3,333 shares Expires not disclosed F1 · derivative.exercise_price: Represents restricted stock units ("RSUs") that vest 12 months from June 15, 2020 ("Grant Date"), provided that these RSUs vest in full on the Issuer's next regularly scheduled annual meeting of stockholders that occurs following the Grant Date, subject to the Reporting Person's continued service to the Issuer through such vesting date or, if earlier, such annual meeting. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. F1 · derivative.exercise_date: Represents restricted stock units ("RSUs") that vest 12 months from June 15, 2020 ("Grant Date"), provided that these RSUs vest in full on the Issuer's next regularly scheduled annual meeting of stockholders that occurs following the Grant Date, subject to the Reporting Person's continued service to the Issuer through such vesting date or, if earlier, such annual meeting. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. F1 · derivative.expiration_date: Represents restricted stock units ("RSUs") that vest 12 months from June 15, 2020 ("Grant Date"), provided that these RSUs vest in full on the Issuer's next regularly scheduled annual meeting of stockholders that occurs following the Grant Date, subject to the Reporting Person's continued service to the Issuer through such vesting date or, if earlier, such annual meeting. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. Read SEC document
June 10, 2020 Filed Jun 12, 2020 20:43 UTC	UFP TECHNOLOGIES INC UFPT · Entity 4409	GrantStock Option (Right to Buy) · Derivative	2,482	$0.00 Strike: $43.95	$0.00	Disclosure SEC source: 0001240679-20-000057 · edgar.xml · derivative · entry 2 KOZIN MARC D · CIK 0001241647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,482 Underlying: Common Stock, $.01 Par Value · 2,482 shares Expires 2030-06-10 Read SEC document
June 10, 2020 Filed Jun 12, 2020 20:43 UTC	UFP TECHNOLOGIES INC UFPT · Entity 4409	GrantCommon Stock, $.01 Par Value	796	$0.00	$0.00	Disclosure SEC source: 0001240679-20-000057 · edgar.xml · nonDerivative · entry 1 KOZIN MARC D · CIK 0001241647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,400 F1 · shares: Represents restricted stock units issued under the issuer's 2009 Non-Employee Director Stock Incentive Plan that are to be settled solely in shares of Common Stock. The units vest with respect to 100% of the shares on May 31, 2021, so long as the recipient continues as a director of the Issuer through the vesting date. Read SEC document
March 10, 2020 Filed Mar 11, 2020 15:08 UTC	UFP TECHNOLOGIES INC UFPT · Entity 4409	SaleCommon Stock, $.01 Par Value	1,000	$47.47	$47,470.00	Disclosure SEC source: 0001240679-20-000044 · edgar.xml · nonDerivative · entry 4 KOZIN MARC D · CIK 0001241647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,604 F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $47.10 to $47.84, inclusive. The reporting person undertakes to provide to UFP Technologies, Inc., any security holder of UFP Technologies, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document
March 10, 2020 Filed Mar 11, 2020 15:08 UTC	UFP TECHNOLOGIES INC UFPT · Entity 4409	SaleCommon Stock, $.01 Par Value	1,133	$46.21	$52,355.93	Disclosure SEC source: 0001240679-20-000044 · edgar.xml · nonDerivative · entry 3 KOZIN MARC D · CIK 0001241647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,604 F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $46.03 to $46.50, inclusive. The reporting person undertakes to provide to UFP Technologies, Inc., any security holder of UFP Technologies, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document
March 10, 2020 Filed Mar 11, 2020 15:08 UTC	UFP TECHNOLOGIES INC UFPT · Entity 4409	SaleCommon Stock, $.01 Par Value	2,600	$45.55	$118,430.00	Disclosure SEC source: 0001240679-20-000044 · edgar.xml · nonDerivative · entry 2 KOZIN MARC D · CIK 0001241647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,737 F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $45.14 to $45.85, inclusive. The reporting person undertakes to provide to UFP Technologies, Inc., any security holder of UFP Technologies, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document
March 10, 2020 Filed Mar 11, 2020 15:08 UTC	UFP TECHNOLOGIES INC UFPT · Entity 4409	SaleCommon Stock, $.01 Par Value	200	$44.84	$8,968.00	Disclosure SEC source: 0001240679-20-000044 · edgar.xml · nonDerivative · entry 1 KOZIN MARC D · CIK 0001241647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,337 F1 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $44.74 to $44.91, inclusive. The reporting person undertakes to provide to UFP Technologies, Inc., any security holder of UFP Technologies, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document
March 06, 2020 Filed Mar 10, 2020 13:24 UTC	UFP TECHNOLOGIES INC UFPT · Entity 4409	Exercise / conversionStock Option (Right to Buy) · Derivative	1,724	$0.00 Strike: $31.20	$0.00	Disclosure SEC source: 0001240679-20-000042 · edgar.xml · derivative · entry 16 KOZIN MARC D · CIK 0001241647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: Not disclosed Underlying: Common Stock, $.01 Par Value · 1,724 shares Expires 2028-06-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
March 06, 2020 Filed Mar 10, 2020 13:24 UTC	UFP TECHNOLOGIES INC UFPT · Entity 4409	Exercise / conversionStock Option (Right to Buy) · Derivative	2,056	$0.00 Strike: $27.05	$0.00	Disclosure SEC source: 0001240679-20-000042 · edgar.xml · derivative · entry 15 KOZIN MARC D · CIK 0001241647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: Not disclosed Underlying: Common Stock, $.01 Par Value · 2,056 shares Expires 2027-06-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
March 06, 2020 Filed Mar 10, 2020 13:24 UTC	UFP TECHNOLOGIES INC UFPT · Entity 4409	Exercise / conversionStock Option (Right to Buy) · Derivative	2,864	$0.00 Strike: $22.02	$0.00	Disclosure SEC source: 0001240679-20-000042 · edgar.xml · derivative · entry 14 KOZIN MARC D · CIK 0001241647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: Not disclosed Underlying: Common Stock, $.01 Par Value · 2,864 shares Expires 2026-06-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
March 06, 2020 Filed Mar 10, 2020 13:24 UTC	UFP TECHNOLOGIES INC UFPT · Entity 4409	Exercise / conversionStock Option (Right to Buy) · Derivative	2,921	$0.00 Strike: $19.97	$0.00	Disclosure SEC source: 0001240679-20-000042 · edgar.xml · derivative · entry 13 KOZIN MARC D · CIK 0001241647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: Not disclosed Underlying: Common Stock, $.01 Par Value · 2,921 shares Expires 2025-06-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
March 06, 2020 Filed Mar 10, 2020 13:24 UTC	UFP TECHNOLOGIES INC UFPT · Entity 4409	Exercise / conversionStock Option (Right to Buy) · Derivative	2,088	$0.00 Strike: $25.04	$0.00	Disclosure SEC source: 0001240679-20-000042 · edgar.xml · derivative · entry 12 KOZIN MARC D · CIK 0001241647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: Not disclosed Underlying: Common Stock, $.01 Par Value · 2,088 shares Expires 2024-06-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.